Stocks Sanofi SA

More

  • NEW YORK, Nov 23- U.S. drug benefit manager CVS Health said on Monday it would add Amgen Inc's Repatha cholesterol treatment to its list of covered drugs for private plans over a competing treatment from Regeneron Pharmaceuticals and Sanofi SA. The FDA approved Repatha and Praluent, made by Regeneron and Sanofi, within weeks of each other last summer for patients...

  • Sanofi whistleblower suit kicks into a higher gear Friday, 20 Nov 2015 | 2:38 PM ET
    The French pharmaceutical group Sanofi-Synthelabo headquaters in Ambares.

    An ex-paralegal claims she knows of "many instances" of Sanofi lawyers destroying documents.

  • LONDON, Nov 20- Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. The U.S. Food and Drug Administration has so far approved 38 novel drugs in 2015, more than the 34 that had been cleared by this stage a year ago and just...

  • LONDON, Nov 20- Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. The U.S. Food and Drug Administration has so far approved 37 novel drugs in 2015, more than the 34 that had been cleared by this stage a year ago and just...

  • LONDON, Nov 20- French drugmaker Sanofi and Britain's AstraZeneca said on Friday they had agreed a direct exchange of 210,000 chemical compounds from their respective libraries in a new twist on the drive to boost open innovation. In a bid to increase the number of leads for new medicines, and save both time and money, pharmaceutical companies are experimenting...

  • Where Warren Buffett is spending more time buying Monday, 16 Nov 2015 | 12:01 PM ET
    Warren Buffett

    Investors need to have exposure to overseas stocks after 6 years of a US bull market. Here's a look at how Buffett gradually went global.

  • Pfizer and Allergan are in talks to create the world's biggest drug company by market value and analysts expect a deal would likely involve Pfizer "inverting", or reversing into the smaller, Irish-registered Allergan. Pfizer has used transactions between companies within its group to allow an Irish subsidiary based in Ringaskiddy- Pfizer Ireland...

  • *Potential for technology highlighted at Berlin conference. FRANKFURT/ LONDON, Nov 12- A molecule that carries the recipe for making drugs inside body cells is exciting scientists and investors alike, attracting hundreds of millions of dollars in a scramble for the next promising area of biotechnology. Privately-held CureVac in the university town of...

  • ORLANDO, Nov 11- An experimental cholesterol fighter being developed by Alnylam Pharmaceuticals and The Medicines Co slashed levels of bad LDL cholesterol and remained effective for six months, according to data from a small, early stage study. The drug, called ALN-PCSsc, cut LDL by more than 50 percent in the 69- subject study presented at the American Heart...

  • Nov 9- A new lawsuit accuses Sanofi SA of stalling development of its multiple sclerosis drug Lemtrada to avoid paying out at least $708 million to rights holders under its 2011 agreement to acquire Genzyme Corp.. Genzyme was in the process of developing Lemtrada when Sanofi bought it. Under the merger agreement, Sanofi issued Genzyme shareholders tradable...

  • An investor watches a share prices board in Tokyo, Japan.

    Asian shares traded mixed on Friday, as investors awaited the release of U.S. jobs data that could provide hints to when the Fed will raise interest rates.

  • *Sanofi to obtain exclusive worldwide licence. PARIS, Nov 5- Sanofi signed a licence deal with Hanmi Pharmaceutical to develop experimental, long-acting diabetes treatments, the French drugmaker said on Thursday, in a deal to revive its diabetes division. Korea- based Hanmi will receive an upfront payment of 400 million euros and is eligible for up to 3.5 billion...

  • PARIS, Nov 5- France's Sanofi said on Thursday that it had signed a license agreement with Korea- based Hanmi Pharmaceutical Co. Ltd. to develop a portfolio of experimental, long-acting diabetes treatments. Hanmi will receive an upfront payment of 400 million euros and is eligible for up to 3.5 billion euros in development, registration and sales milestones,...

  • Nov 4- Regeneron Pharmaceuticals Inc raised Eylea sales growth forecast for the third time this year, after surging sales of the eye drug helped the company beat quarterly profit and revenue estimates. Eylea sales surged 53 percent to $1.11 billion in the third quarter ended Sept. 30. Praluent sales are recorded by partner Sanofi SA and Regeneron shares profits...

  • LONDON, Nov 3- GlaxoSmithKline could file up to 20 new drugs for regulatory approval before 2020 as it seeks to revitalise a portfolio hit by falling sales of best-selling inhaled lung treatment Advair, the company said on Tuesday. Britain's biggest drugmaker is trying to boost low investor expectations for its pipeline by hosting its first research and...

  • LONDON, Nov 3- GlaxoSmithKline said on Tuesday it had the potential to file up to 20 new drugs for approval before 2020 as it seeks to revitalise a portfolio hit by falling sales of best-selling inhaled lung treatment Advair. GSK is still investing in oncology, despite having sold its marketed cancer drugs to Novartis in a $20 billion three-way asset swap that...

  • FACTBOX-Drugs to watch at Roche, Sanofi and GSK Sunday, 1 Nov 2015 | 2:00 AM ET

    Nov 1- GlaxoSmithKline, Roche and Sanofi all hold investor days this week. -Nucala, severe asthma injection, $756 million. -Shingrix, shingles vaccines, $594 million.

  • *New CEO's strategy main focus at Sanofi on Nov. 6. LONDON, Nov 1- Three of Europe's top drugmakers- GlaxoSmithKline, Roche and Sanofi- face health checks this week at high-profile presentations designed to show they can overcome looming market threats. GSK's Andrew Witty and Sanofi's new boss Olivier Brandicourt both need to demonstrate recovery potential,...

  • Peanut butter to Jeep cars: 10 recalls to watch Saturday, 31 Oct 2015 | 5:00 PM ET

    Here are essential details consumers should know to navigate some of this past week's recalls.

  • Early movers: AET, TWC, MRO, MGM, SHW & more Thursday, 29 Oct 2015 | 7:56 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.